196 related articles for article (PubMed ID: 35190207)
21. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
[TBL] [Abstract][Full Text] [Related]
22. Silent High Grade Cervical Intraepithelial Neoplasia in Atypical Smears from Liquid Based Cervical Cytology - Three Years Experience in Thammasat University Hospital.
Lertvutivivat S; Chanthasenanont A; Chanthasenanont A; Muangto T; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4353-4356. PubMed ID: 27797243
[TBL] [Abstract][Full Text] [Related]
23. Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1.
Einstein MH; Roden RBS; Ferrall L; Akin M; Blomer A; Wu TC; Chang YN
Cancer Prev Res (Phila); 2023 Apr; 16(4):219-227. PubMed ID: 36607735
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer-a real-world effectiveness study.
Baandrup L; Maltesen T; Dehlendorff C; Kjaer SK
J Natl Cancer Inst; 2024 Feb; 116(2):283-287. PubMed ID: 37718496
[TBL] [Abstract][Full Text] [Related]
25. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
[TBL] [Abstract][Full Text] [Related]
26. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group
N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
[TBL] [Abstract][Full Text] [Related]
27. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
28. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
[TBL] [Abstract][Full Text] [Related]
29. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
[TBL] [Abstract][Full Text] [Related]
30. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
[TBL] [Abstract][Full Text] [Related]
31. High risk HPV testing in the triage of repeat ASC-US and LSIL.
Veijalainen O; Tuomisaari S; Luukkaala T; Mäenpää J
Acta Obstet Gynecol Scand; 2015 Sep; 94(9):931-6. PubMed ID: 26053676
[TBL] [Abstract][Full Text] [Related]
32. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
[TBL] [Abstract][Full Text] [Related]
34. Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination.
Teoh D; Nam G; Aase DA; Russell R; Melton GB; Kulasingam S; Vogel RI
JAMA Netw Open; 2022 May; 5(5):e2214020. PubMed ID: 35612854
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study.
Tozawa-Ono A; Kamada M; Teramoto K; Hareyama H; Kodama S; Kasai T; Iwanari O; Koizumi T; Ozawa N; Suzuki M; Kinoshita K
Hum Vaccin Immunother; 2021 Apr; 17(4):950-954. PubMed ID: 33121340
[TBL] [Abstract][Full Text] [Related]
36. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
[TBL] [Abstract][Full Text] [Related]
37. Presence of koilocytosis in low-grade smears of high-risk HPV-positive women is a negative predictor for cervical intraepithelial neoplasia grade 3 or more.
Siebers AG; van der Linden H; Vedder JEM; Bekkers RLM; Melchers WLG; Bulten J
Cytopathology; 2018 Jun; 29(3):275-280. PubMed ID: 29575519
[TBL] [Abstract][Full Text] [Related]
38. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
39. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.
Wright TC; Stoler MH; Parvu V; Yanson K; Cooper C; Andrews J
Gynecol Oncol; 2019 Aug; 154(2):360-367. PubMed ID: 31160073
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
